Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Accenture
McKinsey
Chinese Patent Office
Cipla
Covington
Cantor Fitzgerald
Novartis
UBS

Generated: October 18, 2017

DrugPatentWatch Database Preview

Shire Dev Llc Company Profile

« Back to Dashboard

What is the competitive landscape for SHIRE DEV LLC, and when can generic versions of SHIRE DEV LLC drugs launch?

SHIRE DEV LLC has four approved drugs.

There are thirty-nine US patents protecting SHIRE DEV LLC drugs on SHIRE DEV LLC drugs in the past three years.

There are three hundred and seventy-seven patent family members on SHIRE DEV LLC drugs in forty-six countries and six supplementary protection certificates in five countries.

Summary for Applicant: Shire Dev Llc

International Patents:377
US Patents:39
Tradenames:4
Ingredients:4
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc
MYDAYIS
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL022063-001Jun 20, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-003Jan 28, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
MYDAYIS
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL022063-001Jun 20, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-002Jan 28, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-004Jan 28, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-001Jan 28, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-001Jan 28, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-005Jan 28, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SHIRE DEV LLC drugs

Drugname Dosage Strength Tradename Submissiondate
lanthanum carbonate
Oral Powder750 mg and 1000 mg
FOSRENOL
11/25/2015
lisdexamfetamine dimesylate
Capsules20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg
VYVANSE
2/23/2011
lanthanum carbonate
Chewable Tablet500 mg, 750 mg and 1000 mg
FOSRENOL
10/27/2008

Non-Orange Book Patents for Shire Dev Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,752Compounds and compositions for prevention of overdose of oxycodone► Subscribe
7,989,626Modulators of cellular adhesion► Subscribe
8,394,813Active agent delivery systems and methods for protecting and administering active agents► Subscribe
8,133,881Carbohydrate conjugates to prevent abuse of controlled substances► Subscribe
8,263,119Capsule formulations containing lanthanum compounds► Subscribe
8,871,935Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
9,051,297Compositions and methods for treatment► Subscribe
6,716,452 Active agent delivery systems and methods for protecting and administering active agents► Subscribe
7,375,083Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
8,758,776Compositions and methods for treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Shire Dev Llc Drugs

Country Document Number Estimated Expiration
Lithuania2444079► Subscribe
Canada2477088► Subscribe
MexicoPA06003619► Subscribe
Denmark1542660► Subscribe
Israel174683► Subscribe
Japan2007513081► Subscribe
Eurasian Patent Organization200501895► Subscribe
China101175488► Subscribe
Canada2527646► Subscribe
European Patent Office2792363► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Shire Dev Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90058-4Sweden► SubscribePRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201
2008005,C0817639Lithuania► SubscribePRODUCT NAME: LANTANO KARBONATO HIDRATAS; NAT. REGISTRATION NO/DATE: LT/1/07/0776/001-021 20071003; FIRST REGISTRATION: 17192, 2004-03-19 ; 18466, 2004-03-19; 21073, 2004-10-19; 21074 20041029
2013000079Germany► SubscribePRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201
C/GB06/036United Kingdom► SubscribeSPC/GB06/036: 20061027
2013 00043Denmark► SubscribePRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201
2008005Lithuania► SubscribePRODCUT NAME: LANTANO KARBONATO HIDRATAS; NAT. REG. DATE/NO: LT/1/07/0776/001-021; FIRST REG. DATE: 20040319
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
McKesson
Moodys
Fish and Richardson
Medtronic
McKinsey
Cerilliant
QuintilesIMS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot